Nektar’s rezpegaldesleukin meets primary & key secondary endpoints in Phase 2b atopic dermatitis trial

NEKTAR THERAPEUTICS

REZOLVE-AD met primary endpoint: mean EASI improvement from baseline at week 16 for all three rezpegaldesleukin dose arms vs placebo (p<0.001).
EASI-75 achieved by 42-46% of rezpegaldesleukin patients vs 17% placebo; high dose also significant on EASI-90 (25% vs 9%).
Itch NRS (≥4-point reduction) 42% high dose, 35% middle dose vs 16% placebo; vIGA-AD 0/1 significant for q2w arms.
Safety profile consistent: injection site reactions (69.7%) mostly mild/moderate; no increased conjunctivitis, oral ulcers, or infections.
On-target Treg proliferation up to 6-fold; full 52-week data expected early 2026, alopecia areata top-line Q4 2025.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.